The combination of Nektar Therapeutics' investigational interleukin-2 (IL-2) agent NKTR-214 with Bristol-Myers Squibb Co.'s PD-1 inhibitor Opdivo has activity in lung, kidney cancer and melanoma, the partners said at the Society for Immunotherapy and Cancer meeting in November.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?